{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:30:33Z","timestamp":1776353433697,"version":"3.51.2"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,17]],"date-time":"2013-07-17T00:00:00Z","timestamp":1374019200000},"content-version":"vor","delay-in-days":2968,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.seizure.2005.02.004","type":"journal-article","created":{"date-parts":[[2005,3,19]],"date-time":"2005-03-19T18:18:26Z","timestamp":1111256306000},"page":"248-253","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Efficacy and safety of levetiracetam: An add-on trial in children with refractory epilepsy"],"prefix":"10.1016","volume":"14","author":[{"given":"S.","family":"Grosso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Franzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Iannetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Verrotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Cordelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Marchiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Pascotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Spalice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Acampora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Morgese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Balestri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2005.02.004_bib1","first-page":"426","article-title":"A new antiepileptic drug","volume":"72","author":"Shorvon","year":"2002","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.seizure.2005.02.004_bib2","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1046\/j.1528-1157.2001.41300.x","article-title":"Pharmacokinetic study of levetiracetam in children","volume":"42","author":"Pellock","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2005.02.004_bib3","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/seiz.2000.0380","article-title":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy","volume":"9","author":"Betts","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2005.02.004_bib4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1059-1311(02)00258-3","article-title":"Clinical experience of marketed levetiracetam in an epilepsy clinic-a 1 year follow-up study","volume":"12","author":"Betts","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2005.02.004_bib5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S1059-1311(03)00139-0","article-title":"Levetiracetam treatment of idiopathic generalized epilepsy","volume":"12","author":"Krauss","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2005.02.004_bib6","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/WNL.56.12.1772","article-title":"Long-term continuation of levetiracetam in patients with refractory epilepsy","volume":"56","author":"Krakow","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2005.02.004_bib7","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2005.02.004_bib8","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2005.02.004_bib9","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"issue":"Suppl 4","key":"10.1016\/j.seizure.2005.02.004_bib10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1528-1167.2001.00009.x","article-title":"Use of levetiracetam in special populations","volume":"42","author":"French","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2005.02.004_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1090-3798(03)00041-2","article-title":"Effect of levetiracetam in refractory childhood epilepsy syndromes","volume":"7","author":"Lagae","year":"2003","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2005.02.004_bib12","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1528-1157.2002.13101.x","article-title":"Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial","volume":"43","author":"Glauser","year":"2002","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2005.02.004_bib13","first-page":"S45","article-title":"Preliminary efficacy of levetiracetam in children","volume":"5","author":"Glauser","year":"2003","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2005.02.004_bib14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.33588\/rn.3706.2003314","article-title":"Levetiracetam in children and adolescents with epilepsy","volume":"37","author":"Herranz","year":"2003","journal-title":"Rev Neurol"},{"key":"10.1016\/j.seizure.2005.02.004_bib15","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.33588\/rn.3711.2003423","article-title":"Effectiveness and tolerability of levetiracetam in 43 children and adolescents with epilepsy","volume":"37","author":"Herranz","year":"2003","journal-title":"Rev Neurol"},{"key":"10.1016\/j.seizure.2005.02.004_bib16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1177\/088307380201700603","article-title":"Levetiracetam in refractory pediatric epilepsy","volume":"17","author":"Wheless","year":"2002","journal-title":"J Child Neurol"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2005.02.004_bib17","first-page":"S108","article-title":"Levetiracetam in the treatment of Lennox-Gastaut syndrome","volume":"50","author":"De los Reyes","year":"2001","journal-title":"Ann Neurol"},{"issue":"Suppl 7","key":"10.1016\/j.seizure.2005.02.004_bib18","first-page":"S53","article-title":"Levetiracetam adjunct therapy for refractory paediatric generalized epilepsies","volume":"42","author":"Barron","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2005.02.004_bib19","doi-asserted-by":"crossref","unstructured":"Commission on classification and terminology of the International League Against Epilepsy, Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22:489\u2013501.","DOI":"10.1111\/j.1528-1157.1981.tb06159.x"},{"key":"10.1016\/j.seizure.2005.02.004_bib20","doi-asserted-by":"crossref","unstructured":"Commission on classification and terminology of the International League Against Epilepsy, Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389\u2013399.","DOI":"10.1111\/j.1528-1157.1989.tb05316.x"},{"key":"10.1016\/j.seizure.2005.02.004_bib21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1046\/j.1528-1157.2001.10401.x","article-title":"International League Against Epilepsy (ILAE). A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology","volume":"42","author":"Engel","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2005.02.004_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1059-1311(03)00004-9","article-title":"Levetiracetam for benign epilepsy of childhood with centrotemporal spikes-three cases","volume":"12","author":"Bello-Espinosa","year":"2003","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2005.02.004_bib23","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1525-5050(03)00171-9","article-title":"Landau-Kleffner syndrome responsive to levetiracetam","volume":"4","author":"Kossoff","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2005.02.004_bib24","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00431-002-1100-z","article-title":"Successful treatment of pharmacoresistent continuous spike wave activity during slow sleep with levetiracetam","volume":"162","author":"Hoppen","year":"2003","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.seizure.2005.02.004_bib25","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/jnnp.73.4.457","article-title":"Amelioration of spinal myoclonus with levetiracetam","volume":"73","author":"Keswani","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.seizure.2005.02.004_bib26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00004703-200208000-00006","article-title":"Levetiracetam in autistic children: an open-label study","volume":"23","author":"Rugino","year":"2002","journal-title":"J Dev Behav Pediatr"},{"key":"10.1016\/j.seizure.2005.02.004_bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0920-1211(00)00124-8","article-title":"Assessing risk to benefit ratio in antiepileptic drug therapy","volume":"41","author":"Perucca","year":"2000","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2005.02.004_bib28","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1046\/j.1528-1157.2001.32101.x","article-title":"Levetiracetam psychosis in children with epilepsy","volume":"42","author":"Kossoff","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2005.02.004_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1059-1311(03)00111-0","article-title":"Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam","volume":"13","author":"Mula","year":"2004","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2005.02.004_bib30","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1212\/01.WNL.0000078031.32904.0D","article-title":"Psychiatric adverse events during levetiracetam therapy","volume":"61","author":"Mula","year":"2003","journal-title":"Neurology"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131105000373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131105000373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:33:38Z","timestamp":1761010418000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131105000373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S1059131105000373"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2005.02.004","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of levetiracetam: An add-on trial in children with refractory epilepsy","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2005.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}